BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $10,820.50 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 425 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $10,820.50. Following the completion of the sale, the executive vice president now owns 262,198 shares of the company's stock, valued at $6,675,561.08. The trade was a 0.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

BioLife Solutions Price Performance

BioLife Solutions stock traded down $0.97 during midday trading on Friday, reaching $25.83. The company had a trading volume of 608,317 shares, compared to its average volume of 283,669. The company has a market capitalization of $1.21 billion, a P/E ratio of -24.37 and a beta of 2.04. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The firm's fifty day simple moving average is $26.65 and its 200-day simple moving average is $25.49. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same period last year, the company posted ($0.21) EPS. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Remove Ads

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of BioLife Solutions by 13.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider's stock worth $1,835,000 after buying an additional 8,258 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $31,000. Point72 Asset Management L.P. acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $11,113,000. ProShare Advisors LLC acquired a new stake in BioLife Solutions in the 4th quarter valued at approximately $282,000. Finally, Millennium Management LLC increased its holdings in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. HC Wainwright upped their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday. KeyCorp upped their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. TD Cowen increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Northland Securities increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. Finally, Benchmark reaffirmed a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.